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Abstract: Protected telomeres ensure normal chromosomal segre-
gation during mitosis but at the same time can endow genetically
abnormal cancer cells with immortality. Telomerase has a pivotal
role in telomere protection, both in normal and cancer cells. Under-
standing the functional interplay between telomere shortening and
telomerase expression in cancer cells is of critical importance to
elucidating the precise mechanisms by which these cells are able to
bypass telomere crisis and become immortal.
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TELOMERES: AN ANTICANCER BARRIER
Telomeres are the ends of linear genomes. Made of
multiple copies of a TTAGGG sequence, telomeres protect
chromosomes from degradation, irregular recombination and
end-to-end fusions.1 Normally, a sheltering complex—shel-
terin—composed of at least six telomere associated proteins,
caps the telomeres, protecting them from being recognized as
double strand breaks by the DNA damage response (DDR).2
Telomeres shorten with every cell division. Somatic primary
cells in cell culture shorten their telomeres by 50 to 200 base
pairs after each round of replication until they reach a critical
length below which the shelterin complex becomes ineffi-
cient. This leaves the telomeres “un-capped,” which in turn
activates the DDR and triggers cellular senescence.1,2 This
process is known as the “mitotic clock for aging.”3 The
current hypothesis of telomere involvement in cancer (Figure
1A) states that proliferative preneoplastic cells suffer persis-
tent telomere shortening leading to massive senescence (mor-
tality stage I) in all but a few positively selected cells, which
are able to bypass senescence by altering their DDR by
mutation or silencing of DDR-related proteins such as ataxia
telangiectasia mutated, p53, and p16.4 These cells extend
their life span and continue losing telomere fragments until
their telomeres become dysfunctional, causing genomic in-
stability and subsequent apoptosis (mortality stage 2). Ac-
cording to this model, during this process a small subpopu-
lation of cells is able to avoid apoptosis by maintaining their
telomere length. Telomere length maintenance at this stage is
related to the expression of telomerase, which adds TTAGGG
fragments to the end of the telomeres, lengthening and main-
taining them in the capped conformation. More rarely, telo-
mere elongation can also be achieved through homologue
recombination between telomeric sequences: the alternative
lengthening mechanism. Thus, according to the current
model, the progeny of the few, genetically unstable, immortal
cells that escape both mortality stages may allow the progres-
sion of a preneoplastic lesion towards malignant stages.1,3–6
Telomerase is a large DNA polymerase ribonucleopro-
tein (RNP) complex containing an RNA subunit (telomerase
RNA component [TERC]) and a protein component (telom-
erase reverse transcriptase [TERT]). Most somatic cells do
not show detectable telomerase activity mainly because of
lack of telomerase expression. However, stem and embryonic
cells do express telomerase as a mechanism to prevent telo-
mere attrition.7
TELOMERE MAINTENANCE AND TELOMERASE
REGULATION
Because of its importance for cell fate, telomere length
is finely regulated. Telomerase activity is the main mecha-
nism for telomere maintenance and thus, telomerase activity
itself is also carefully controlled (Figure 1B).
The active telomerase RNP consists of three subunits:
the telomerase reverse transcriptase (TERT), the TERC, and
dyskerin 1.8 The catalytic activity of this enzyme resides in
the TERT component, and thus the regulation of TERT
mRNA expression seems to be the most important step for
telomerase activation. In this context, many oncogenic and
tumor suppressor pathways have been shown to regulate
TERT mRNA transcription. C-myc, RAS, E6, STAT 3, and
estrogens are activators of TERT, whereas Mad 1, p53,
TGF-, RAK, BRIT1, and MDM2 are inhibitors. TERT
transcription is also regulated by epigenetic modifications of
its promoter, which contains clusters of CpG islands which
can be methylated, and thus silenced, by DNA methyl trans-
ferases. Besides transcriptional regulation, TERT activity
may be regulated by alternative splicing and posttranslational
modifications.7 Active telomerase RNP requires that tran-
siently expressed TERT assembles with constitutively accu-
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FIGURE 1. A, Theoretical model of the association between telomere length and the carcinogenesis process. The cells contin-
uously proliferating in preneoplastic lesion suffer persistent telomere shortening leading to senescence (mortality stage I).
Some cells are able to bypass senescence by altering their DDR and keep proliferating. These cells extend their lifespan until
their telomeres become dysfunctional, entering apoptosis (mortality stage II). A small subpopulation of cells with genetic ab-
normalities escapes both mortality stages and progress towards malignancy. B. Summary of the telomerase regulation and
telomere elongation pathway. Abbreviations: telomerase reverse transcriptase (TERT), telomerase RNA component (TERC),
RNA polymerase II (RNA POL II), dyskerin (DKC), telomerase ribonucleoprotein (telomerase RNP), telomeric repeat-binding
factor (TRFs) 1 and 2, TRF1-interacting nuclear factor 2 (TIN2), TRF2-interacting protein 1 (Rap1), adrenocortical dysplasia
protein homolog (TPP1), and protection of telomeres protein 1 (POT1).
Fernandez-Garcia et al. Journal of Thoracic Oncology • Volume 3, Number 10, October 2008
Copyright © 2008 by the International Association for the Study of Lung Cancer1086
mulated TERC-dyskerin complexes. This assembling process
requires the presence of HSP90. Recent studies show that
alterations in TERC processing can limit telomerase activity.9
Besides telomerase RNP regulation, telomere mainte-
nance depends on telomere structure as well. At least two
factors have been shown to regulate telomere structure: telo-
mere chromatin modifications and alterations of the telomere-
binding protein complex. Both factors determine whether the
telomeres are in a “closed” or “open” conformation to allow
telomerase RNP-based elongation.2,3,7 The shelterin protein
complex is formed by six telomere-specific binding factors:
telomeric repeat-binding factors (TRFs) 1 and 2, TRF1-
interacting nuclear factor 2 (TIN2), TRF2-interacting protein
1 (Rap1), adrenocortical dysplasia protein homolog (TPP1)
and protection of telomeres protein 1 (POT1). They are in
charge of maintaining the telomere “capped,” making it
invisible to the DDR. Alterations in the shelterin proteins cause
telomere “un-capping” and cell senescence.2,7 The telomere
open status is also driven by the enzyme Tankyrase.10
Finally, telomerase ability to maintain telomere length
also depends on the accessibility of the active telomerase
RNP to each telomere that requires elongation. Telomerase
RNP does not elongate all telomeres at the same time and it
seems to act preferentially on the shortest telomeres of the
cell during the S phase of the cycle.11,12
TELOMERES AND TELOMERASE REGULATION
IN LUNG CANCER
Telomerase is expressed in most human cancers, in-
cluding lung cancers. As in many other cancer types, lung
cancer cells avoid the progressive attrition of telomeres by
expressing telomerase. Using a polymerase chain reaction-
based telomeric repeat amplification protocol assay, early
studies reported finding telomerase activity in most primary
lung cancer samples.13,14 Furthermore, several studies using
animal models and human non-small cell lung cancer
(NSCLC) tissues have reported that TERT mRNA and TERT
protein are overexpressed in lung cancer biopsies compared
with normal lung tissues.4,15
In recent years, the oncogenic nature of telomerase has
been a debatable issue. In an exhaustive review, Harley16
provided strong arguments against this concept. Supporting
that line of evidence, recent experimental data show that
reintroduction of telomerase in low telomerase expressing
somatic cells does not transform them. Ramirez et al.17
overexpressed cyclin-dependent kinase 4 and hTERT in hu-
man bronchial epithelial cells, resulting in immortal cell lines,
pointing to the necessity of bypassing senescence before cell
immortalization with telomerase. Cyclin-dependent kinase 4
overexpression prevented p16INK4a-associated senescence
induced by the in vitro culture conditions (mortality stage I),
whereas expression of hTERT bypassed telomere dysfunction
(mortality stage II). The created cell lines provide a useful
model that can be genetically manipulated to identify genetic
and epigenetic differences between tumor and normal cells.
In fact, using these immortalized human bronchial epithelial
cells, the same group has more recently reported that p53
knockdown, K-RASV12, and mutant epidermal growth factor
receptor contribute to lung cancer tumorigenesis, but are not
enough to achieve full malignant transformation and in vivo
tumor formation.18
Recently, a mutated version of the mouse telomerase
catalytic subunit (mTerc) has been incorporated to the well-
characterized K-rasG12D mouse lung cancer model.
K-ras(G12D) mTerc(/) mice with telomere dysfunction
but intact p53 exhibited increased lung epithelial apopto-
sis, delayed tumor formation, and increased life span
relative to K-ras(G12D) mTerc(/) mice with intact
telomere function.19
Lantuejoul et al.4 proposed that telomere length dimin-
ishes throughout the multistep human lung carcinogenesis
progression until a point when a stable short length is reached
and telomerase is activated. Telomere length is decreased in
atypical adenomatous hyperplasias and bronchioalveolar car-
cinomas concomitant with positive expression of hTERT
mRNA, indicating telomere dysfunction in the earliest phase
of pulmonary carcinogenesis.20 Several studies have been
published on the expression of telomerase in preneoplastic
lesions in lung cancer and in other tumors. In general, these
reports show an increase in telomerase expression at the late
dysplastic lesions. These immunocytochemical studies have
been carried out by means of commercially available anti-
bodies, the specificity of which has been recently chal-
lenged.4,21 Validation studies with new highly specific anti-
bodies are needed to confirm the reported data on expression
of telomerase and other related proteins.
Mechanisms for telomerase activation in lung cancer
cells are not known yet. Comparative genomic hybridization
studies in samples from early stages of NSCLC have shown
that the genomic region that harbors hTERT gene, 5p15.33, is
frequently amplified when compared with normal tissues.22
Mutations in TERT or TERC that result in telomere shorten-
ing confer increase in susceptibility to adult-onset idiopathic
pulmonary fibrosis.23 However, none of these mutations have
been associated to lung cancer. The expression of other
telomere-associated proteins has been also reported as altered
in lung cancer. Quantitative polymerase chain reaction stud-
ies showed that TRF1 expression is lower in NSCLC tissues
when compared with the adjacent normal tissues.24
TELOMERES AND ANTICANCER THERAPIES
The differences between normal and cancer cells in
terms of telomerase expression and telomere length provide a
therapeutic opportunity for telomerase inhibition-based ther-
apies. Cancer patients are less likely to develop resistance to
telomerase-based therapies than to other cancer drugs, and
telomerase-based therapies are unlikely to cause tissue tox-
icity to normal nontelomerase expressing cells.6
There are two different approaches for telomerase-
based therapies that have already been used in clinical trials:
direct enzyme inhibition and active telomerase immunother-
apy. Different compounds with telomerase activity inhibition
properties have been studied in vitro and in animal models.
Three of them, BIBR1532, GRN163, and GRN163L have
been proven to have anticancer properties in several animal
models.25 Other small-molecule modulators of telomerase/
Journal of Thoracic Oncology • Volume 3, Number 10, October 2008 Telomeres and Telomerase in Lung Cancer
Copyright © 2008 by the International Association for the Study of Lung Cancer 1087
telomere biology, notably G-quadruplex ligands such as
RHPS4, are in preclinical development.26 GRN163L is the
only one being tested in humans. Four trials with this oligo-
nucleotide-based compound targeting the telomerase RNA
template are in phase I for different cancer types. Specifically,
study NCT00510445 was designed to determine the safety
and the maximum tolerated dose of GRN163L when admin-
istered in combination with a standard paclitaxel/carboplatin
regimen to patients with advanced or metastatic NSCLC.
This lung cancer trial is the first to study GRN163L in
combination with standard chemotherapy. Recruitment for
this study is due to be completed in December 2008.6
Cancer immunotherapies use self antigens up-regulated
in cancer cells, to overcome self-recognition by normal cells.
Currently, there are some products which use synthetic TERT
peptides to induce antigen-presenting cells to produce an
immune response against cancer cells expressing TERT an-
tigens. The most advanced ones are GV1001 and GRNVAC1.
Trial NCT00509457 was designed to examine the safety and
efficacy of GV1001 telomerase peptide vaccination in pa-
tients with NSCLC after having been treated with conven-
tional therapy with radiotherapy and docetaxel as a radiosen-
sitizer. The trial started in November 2006 and is still
recruiting patients.6 The vaccine Vx-001 using a hTERT cryp-
tic peptide has completed a “proof of principle” Phase I/II
clinical trial presented at ASCO 2008. Vx-001 has also obtained
an orphan drug designation for NSCLC from EMEA.27
The results of the mentioned clinical trials, and new
trials designed to test new antitelomerase drugs need to be
followed carefully as they may provide new avenues for
isolated or combined targeted therapies for lung cancer. It
could be of interest to see if there is a gene signature linked
to the molecular status of telomere-related proteins that could
predict the response to telomerase inhibitors. The question
about the relevance of telomeres and telomerase pathway for
lung cancer therapy will hopefully be solved in the very next
future.
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